NCT07014618Recruiting
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Impact of Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on supporting patients through their radiation care, as well as their influence on adherence to standard of care treatment modalities.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 420 (estimated)
- First submitted
- 13 May 2025
- Start date
- 16 Oct 2025
- Primary completion date
- 31 Oct 2029
- Lead sponsor
- University of Oklahoma
- Diseases
- Prostate cancer
- NCT number
- NCT07014618
What you commit to
- Study type: Observational
- Planned participants: 420
- From 16 Oct 2025 to the primary completion date, 31 Oct 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects WITHOUT histologically/cytologically confirmed Breast or Prostate Cancer.
Age
- Subjects younger than 18 years old.
Other
- Subjects NOT of African American race, Native American race or Hispanic ethnicity.
Who the study is looking for
- Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer.
- Subjects must be 18 years of age or older. This study requires informed consent by the subject.
- Subjects must be of African American race, Native American race, or Hispanic ethnicity.
- Subjects scheduled to undergo RT for Cancer Treatment.
- Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| OU Health Stephenson Cancer Center Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.